Based on insights from interviews with key opinion leaders, this report provides an in depth look into the current and future treatment landscape for Parkinson's Disease, focusing on the efficacy, challenges, and potential of existing and pipeline therapies. Gain a comprehensive understanding of treatment algorithms, unmet needs, and the evolving therapeutic strategies, including the role of levodopa, emerging therapies like GLP-1 agonists, and innovative brain infusion techniques.
Key questions answered:
What treatments currently form the backbone of Parkinson's Disease therapy?
What are the advantages and disadvantages of these treatments?
What are the current unmet needs and challenges in treating Parkinson's Disease?
Which products are currently in the development pipeline, and what impact are they expected to have on treatment pathways?
Do any of the current pipeline therapies address unmet treatment needs?
How is the Parkinson's Disease treatment landscape expected to evolve over the next three to five years?
This report is based on the leading insights from interviews with six key opinion leaders (KOLs) from the USA and six from Europe. FirstWord's research and analysis for Therapy Trends KOL Insight: Parkinson's Disease identified the following major findings:
Current and future treatment algorithm
Research objectives
Current treatment practice and unmet needs in Parkinson's disease
Key insights summary
First-line treatment for PD is usually either levodopa, a dopamine agonist or a MAO-B inhibitor, depending on age, activity, severity of symptoms and formulation convenience
New directions in Parkinson's disease therapy
Key insights summary
Promising new directions in PD treatment include subcutaneous levodopa, LRRK2 targeting, repurposed GLP-1 agonists and brain infusion of dopamine
Disease modification remains elusive in PD, but the next five years should see better and earlier symptomatic treatment, together with more attention to non-motor symptoms
